This review discusses how chimeric antigen receptor (CAR) T cells could treat metastatic melanoma. The authors outline specific strategies including combination approaches that could be used to overcome some limitations of CAR T cell therapy for metastatic melanoma.
This recent article explains that the incidence of melanoma has increased, but mortality has declined with improved management.
The aim of this recent study was to evaluate the association of performing a sentinel lymph node biopsy (SLNB) with overall survival in intermediate thickness melanoma patients in a Dutch population-based daily clinical setting. The study concludes that SLNB in patients with intermediate-thickness melanoma on trunk or limb resulted in a 14% absolute and significant 10-year survival difference compared to those without SLNB.
This review provides an insight into available data on circulating and tissue biomarkers, including the tumor microenvironment and associated gene signatures, and their predictive and prognostic role during neoadjuvant and adjuvant treatment for cutaneous high-risk melanoma patients.
According to this recent study, higher cumulative exposure to thiazides was associated with increased rates of incident skin cancer in people aged 66 years and older. Consideration of other antihypertensive treatments in patients at high risk of skin cancer may be warranted.
This review aims to provide a comprehensive overview of the current knowledge regarding conjunctival melanoma (CoM), with a focus on the genetic and immunologic understanding. The authors elaborate on the distinct position of CoM in contrast to other types of melanoma, and explain how new insights in the pathophysiology of this disease guide the development of new, personalized, treatments.
According to this recent study, early time to recurrence (TTR) predicts worse survival and could be considered an independent prognostic factor for patients with localized or regionally advanced cutaneous melanoma. TTR should be evaluated in all patients with recurrence to guide post-recurrence risk stratification and follow-up schedules.
According to this recent study, estimated mean prevalence of sunbed use was 0.6% for 11- to 14-year-olds and 2.5% for 15- to 17-year-olds, equating to 62,130 children using sunbeds in England. A predicted 2958 premises and 17,865 sunbeds exist nationally and a ‘buy-back’ scheme would cost approximately GBP 21.7 million.
Results of this recent study support the role of the BRAF variant allele frequency (percentage of mutated alleles) as a potential prognostic and predictive biomarker in melanoma patients in the context of BRAF inhibition.
According to this recent study, in patients who are resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 seemed to yield higher efficacy than ipilimumab with a higher objective response rate, longer progression-free, and longer overall survival, with a similar rate of grade 3–5 toxicity. The study concludes that ipilimumab plus anti-PD-1 should be favoured over ipilimumab alone as a second-line immunotherapy for these patients with advanced melanoma.